Triple-negative breast cancer (TNBC) is characterized by limited pharmaceutical treatment options as therapy relevant expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) is missing. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.